Derma Sciences's EPS (Basic) for the
three
months ended in Sep. 2016 was $-0.05.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2016 was $-0.40.
Derma Sciences Earnings per Share (Diluted) Historical Data
The historical data trend for Derma Sciences's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Derma Sciences's Earnings per Share (Diluted)
For the Medical Instruments & Supplies subindustry, Derma Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Derma Sciences's PE Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Derma Sciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Derma Sciences's PE Ratio falls into.
Derma Sciences Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Derma Sciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2015 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Derma Sciences (NAS:DSCI) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Derma Sciences Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Derma Sciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Derma Sciences (Derma Sciences) Business Description
Derma Sciences Inc was incorporated on September 10, 1984. The Company is a tissue regeneration company engaged in three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that initiated its Phase 3 study. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels to care givers. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In Pharmaceutical Wound Care, the DSC127 product is in clinical trial for the treatment of diabetic foot ulcers. The Phase 3 clinical trial for diabetic foot ulcers is expected to be completed by the end of 2015. In addition to the diabetic foot ulcer indication, the Company has begun preclinical testing for scar reduction. The product lines in Advanced Wound Care include MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB, BIOGUARD, and ALGICELL AG. The Traditional Wound Care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. In addition, the Company owns or licenses over 50 U.S. patents, corresponding foreign patents and patent applications. The patents relating to the DSC127, MEDIHONEY, BIOGUARD, AMNIOEXCEL and AMNIOMATRIX technologies are held under license agreements of indefinite duration. It is subject to the regulation regarding occupational safety, laboratory practices, environmental protection and hazardous substance control and may be subject to other present and future U.S. and foreign regulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DSCI has been successfully added to your 